NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics has priced its initial public offering at $10 per share with gross proceeds expected at $8.5 million.

The company is offering 850,000 shares of its common shares in its IPO and has granted the underwriters a 45-day option to purchase up to 127,500 additional shares to cover any overallotments. Aegis Capital is the sole book-running manager on the offering.

Signal's shares began trading today on the Nasdaq Capital Market under ticker symbol "SGNL."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.